West Pharmaceutical Services (WST) has just posted Q2 2026 results with revenue of US$872.3 million, basic EPS of US$2.18 and net income of US$154 million, setting the tone for how investors assess its current profitability. The company has seen quarterly revenue move from US$766.5 million in Q2 2025 to US$872.3 million in Q2 2026, while basic EPS shifted over the same period from US$1.83 to US$2.18, giving investors a clear view of how the top line and per share earnings have tracked together. With a trailing twelve month net profit margin at 17% versus 16.5% a year ago, the latest print highlights how efficiently West Pharmaceutical Services is converting sales into profit.

See our full analysis for West Pharmaceutical Services.

With the latest numbers on the table, the next step is to see how this earnings profile lines up against the prevailing narratives around West Pharmaceutical Services, and where those stories might need to be updated.

West Pharmaceutical margin story in focus

• On a trailing twelve month basis, West Pharmaceutical’s net profit of US$564.9 million on US$3.3b in revenue translates to a 17% net margin, compared with 16.5% a year earlier in the provided data.
• Consensus narrative highlights higher margin High Value Product components and drug handling as key profit drivers, and the current 17% margin ties into that by:
  • Linking margin strength to mix shift, where GLP-1 related products accounted for about 7% of revenue earlier in the period and are expected in the consensus view to support higher margin contracts.
  • Aligning the 15.8% trailing year earnings growth with the idea that more business in higher margin areas can help earnings outpace the 6.3% forecast revenue growth.

Investors watching how these margin trends connect to the bullish expectations on higher margin products may want to see how the full community view frames the trade off between mix benefits and execution risks over time. 🐂 West Pharmaceutical Services Bull Case

West Pharmaceutical earnings outpacing sales

• Over the last 12 months, revenue of about US$3.3b is forecast in the data to grow around 6.3% per year, while earnings growth is pegged at roughly 10.95% per year and has already risen 15.8% over the past year.
• Consensus narrative points to automation and higher margin components as the explanation for earnings running ahead of sales, and that view meets some pushback from the risk list:
  • Restructuring and a shift in contract manufacturing, including exiting CGM contracts, are mentioned as factors that could make margins and revenue less consistent even if earnings have recently grown faster.
  • Tariffs and potential pricing pressure are also cited as risks that could eat into the current gap between earnings growth and the softer 6.3% revenue growth outlook.

Valuation caught between peers and industry

• At a share price of US$328.20, West Pharmaceutical is trading about 5.3% below the stated DCF fair value of roughly US$346.45, with a P/E of 40.9x compared with 43x for peers and 36.6x for the wider Global Life Sciences industry.
• Consensus narrative frames this as a premium business with room for growth, and the current numbers give both support and challenge to that idea:
  • The modest discount to DCF fair value and slightly cheaper P/E versus direct peers line up with the view that the recent 15.8% earnings growth and forecast 10.95% growth rate could justify paying near current multiples.
  • At the same time, the five year earnings trend, which the data shows declined about 5% per year, along with a P/E above the broader industry average, adds weight to the more cautious side of the debate on how much to pay for that growth profile.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for West Pharmaceutical Services on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the mixed sentiment around West Pharmaceutical Services has you weighing both the bullish and cautious angles, consider reviewing the data yourself and pressure testing the narrative against your own expectations. You can then round out that view by checking the 4 key rewards.

See What Else Is Out There

For all the positives in West Pharmaceutical Services, the tension between a rich P/E multiple and a softer five year earnings trend stands out as a clear weakness.

If you are questioning whether that premium is worth paying right now, it makes sense to compare West Pharmaceutical Services with companies screened as 49 high quality undervalued stocks to see where the balance of price and fundamentals looks more compelling.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.